Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15505237 | 0.74 | CHRNA7 (0.50) | CHRNA7HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL16992195 | 0.74 | CHRNA7 (0.50) | CHRNA7HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL19459064 | 0.74 | CHRNA7 (0.56) | CHRNA7HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL10130728 | 0.74 | CHRNA7 (0.50) | CHRNA7HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL190568 | 0.74 | CHRNA7 (0.50) | CHRNA7HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL13290568 | 0.73 | CHRNA7 (0.46) | CHRNA7HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL681912 | 0.73 | CHRNA7 (0.46) | CHRNA7HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL6660188 | 0.73 | CHRNA7 (0.46) | CHRNA7HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL13290572 | 0.73 | CHRNA7 (0.46) | CHRNA7HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL13290580 | 0.73 | CHRNA7 (0.46) | CHRNA7HRH3KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442977-B1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORP (US) | 2023-06-28 | — | — | EP | claimed |
| CN-109311889-B | Activin receptor-like kinase inhibitors | 缆图药品公司 | 2021-11-16 | — | — | CN | claimed |
| EP-3442977-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | Blueprint Medicines Corporation (US) | 2019-02-20 | — | — | EP | claimed |
| CN-109311889-A | Activin receptor-like kinase inhibitors | 蓝图药品公司 | 2019-02-05 | — | — | CN | claimed |
| WO-2017181117-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2017-10-19 | — | — | WO | claimed |
| US-20240158398-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2024-05-16 | — | — | US | disclosed |
| EP-4285996-A2 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | Blueprint Medicines Corporation (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3442977-B1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORP (US) | 2023-06-28 | — | — | EP | disclosed |
| US-11634422-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| CN-109311889-B | Activin receptor-like kinase inhibitors | 缆图药品公司 | 2021-11-16 | — | — | CN | disclosed |
| US-10669277-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200031830-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2020-01-30 | — | — | US | disclosed |
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3442977-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | Blueprint Medicines Corporation (US) | 2019-02-20 | — | — | EP | disclosed |
| CN-109311889-A | Activin receptor-like kinase inhibitors | 蓝图药品公司 | 2019-02-05 | — | — | CN | disclosed |
| WO-2017181117-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669277-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | CHRNA7 1308/4885HRH3 2428/4885KDM4E 1819/4885 |
| US-20240158398-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | CHRNA7 1308/4885HRH3 2428/4885KDM4E 1819/4885 |
| US-20200031830-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | CHRNA7 1308/4885HRH3 2428/4885KDM4E 1819/4885 |
| US-11634422-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | CHRNA7 1308/4885HRH3 2428/4885KDM4E 1819/4885 |
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | CHRNA7 1425/4885HRH3 2988/4885KDM4E 2447/4885 |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | CHRNA7 1308/4885HRH3 2428/4885KDM4E 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.